This document can be used to prepare or evaluate feasibility of ancillary study proposals and paper proposals, but is NOT intended for publication.

Breast Cancer Outcome Details (Form 122/130)

File Name	Data as of	Population	Data collected	One row per	Rows
outc_bc_inv.dat	2/17/2024	CT+OS	Main, Ext1, Ext2	Outcome Form	14,267

This file has one row for every form 122 or 130 recording in situ or invasive breast cancer outcome(s). A participant may have more than one of these forms. Only the first occurrence of each outcome is counted, e.g. Limiting the file to rows where BREASTINV=1 will find a single row for each participant with a invasive breast cancer outcome. Breast Cancers derived solely from a cause of death do not have an associated form 122 or 130 so are not included.

ID - WHI Participant Common ID

Col 1

N	Missing
14,267	0

ASCSOURCE - Ascertainment Source

Col 2

Value	Description	N	%
1	Local Form 122	1	0
2	Central Form 130	14,266	100

BREASTINV - Breast Cancer Invasive

Col 3

Usage Notes:

Defined as a breast cancer from a Death or the first adjudication where the form 122 or 130 details indicate an invasive cancer. Breast Cancer Invasive is adjudicated for CT and OS participants. WHI adjudicated all reports of breast cancer for a ppt until the first invasive Breast Cancer. i.e. The first Invasive Breast Cancer may not be the first Breast Cancer. This file does not include cancers determined solely by the cause of death.

Value	Description	N	%
0	No	0	0
1	Yes	11,676	81.8
	Missing	2,591	18.2%

BREASTINSITU - Breast Cancer In Situ

Col 4

Usage Notes:

Defined as the first breast cancer where the form 122 or 130 details indicate an in situ cancer. Breast Cancer In Situ is adjudicated for CT and OS participants. Breast Cancer In Situ occurring on or after a Breast Cancer Invasive is not counted.

Value	Description	N	%
0	No	0	0
1	Yes	2,591	18.2
	Missing	11,676	81.8%

ICDCODE - ICD-O-2 site code

Col 5

Usage Notes:

All centrally adjudicated cancers (F130) have an ICD-O-2 code. The only locally adjudicated cancers with a code are those marked as "other" on F122. F122 codes do not include a decimal. See the SEER coding section of the data prep/use document for details. A description of the ICD site codes can be found in the reference file seer_icd_site_codes.dat by merging on the ICDCODE variable.

N	Missing
14,266	1

BEHAVIOR - Tumor Behavior

Col 6

Usage Notes:

For cancers that have been SEER coded, tumor behavior comes from the 5th digit of the morphology (see MRPHHISTB). For cancers that have not been SEER coded, F130/Question 3 or F122/Question 4 is used.

Value	Description	N	%
1	Invasive	11,676	81.8
2	In Situ	2,591	18.2
3	Borderline	0	0
9	Unknown	0	0

RPRTSRC - Reporting source

Col 7

Reporting Source: (Mark only one. If more than one category applies, mark the first applicable category.)

Value	Description	N	%
1	Hospital inpatient	5,251	36.8
2	Hospital outpatient/radiation/chemo, surgical center, clinic	8,985	63
3	Laboratory only including pathology office	25	0.2
4	Physician's office/private medical practitioner	4	0
5	Nursing/convalescent home/hospice	1	0
6	Autopsy only	0	0
7	Death certificate only	0	0
	Missing	1	0%

DIAGSTAT - Diagnostic confirmation status

Col 8

Diagnostic Confirmation Status: (Mark only one. If more than one category applies, mark the first applicable category.)

Value	Description	N	%
1	Positive histology (pathology)	14,136	99.1
2	Positive exfoliative cytology, no positive histology	19	0.1
3	Positive histology (pathology), regional/distant meta. site	90	0.6
4	Positive micro confirmation, method not specified	1	0
5	Positive laboratory test/marker study	1	0
6	Direct visualization w/o microscopic confirm	0	0
7	Radiography & other imaging techniques w/o micro confirm	11	0.1
8	Clinical diagnosis only (other than 5, 6, 7)	8	0.1
9	Unknown if microscopically confirmed	0	0
	Missing	1	0%

LATERAL - Laterality

Col 9

Value	Description	N	%
0	Not a paired site	0	0
1	Right - origin of primary	6,957	48.8
2	Left - origin of primary	7,282	51
3	Only one side right or left unspecified	1	0
4	Bilateral involvement, lateral origin unknown single primary	0	0
5	Paired site, no lateral info, midline tumor	26	0.2
	Missing	1	0%

MRPHHISTB - Morphology - histology/behavior

Col 10

Morphology: first 5 digits

Usage Notes:

ICD-O-2 codes were used for all cancers except Lymphoma and Leukemia. WHI used ICD-O-3 codes for those cancers. WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details. A description of the histology/behavior codes can be found in the reference file seer_icd_hist_codes.dat by merging on the MRPHHISTB variable.

N	Missing
14,266	1

GRADING - Morphology - grading

Col 11

Morphology: 6th digit

Usage Notes:

WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details.

Value	Description	N	%
1	Well differentiated	3,216	22.5
2	Moderately differentiated	5,839	40.9
3	Poorly differentiated	3,289	23.1
4	Anaplastic	659	4.6
5	T-Cell	0	0
6	B-Cell	0	0
7	Null cell	0	0
8	NK Cell	0	0
9	Unknown/not done	1,263	8.9
	Missing	1	0%

SIZE - F130 EOD SEER - Size

Col 12

Evidence of Disease (SEER): digits 1-3

Usage Notes:

When size doesnt make sense, this field is used for other purposes (e.g. Leukemias have no size, this field records AIDS status). Size is usually measured in mm, though it may vary by cancer type. Even for cancers that do have a size, not all values indicate an actual size (e.g. 2 for many cancers means "<=2mm", but for breast cancer it means "Mammographic diagnosis only, tumor not clinically palpable" ). WHI used the SEER 1988, 2nd edition rules for coding cancers. See the SEER coding section of the data prep/use document for details.

N	Missing	Min	Max	Mean	StdDev
14,266	1	0	999	81.105	244.713

EXTENSION - F130 EOD SEER - Extension

Col 13

Evidence of Disease (SEER): digits 4-5

Usage Notes:

WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details.

N	Missing	Min	Max	Mean	StdDev
14,266	1	0	99	10.658	13.604

INVOLVE - F130 EOD (SEER) - Lymph node involvement

Col 14

Evidence of Disease (SEER): digit 6

Usage Notes:

WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details.

N	Missing	Min	Max	Mean	StdDev
14,266	1	0	9	0.824	2.009

POSLYMPH - F130 EOD (SEER) - Number of positive lymph nodes

Col 15

Evidence of Disease (SEER): digits 7-8

Usage Notes:

WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details.

N	Missing	Min	Max	Mean	StdDev
14,266	1	0	99	26.527	42.971

NUMLYMPH - F130 EOD (SEER) - Number of lymph nodes examined

Col 16

Evidence of Disease (SEER): digits 9-10

Usage Notes:

WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details.

N	Missing	Min	Max	Mean	StdDev
14,266	1	0	99	6.391	11.71

STAGE - Summary Stage (SEER)

Col 17

Usage Notes:

WHI used SEER 1988, 2nd edition rules when coding cancers, see the SEER coding section of the data prep/use document for details.

Value	Description	N	%
1	In Situ	2,585	18.1
2	Localized	8,798	61.7
3	Regional	2,554	17.9
4	Distant	198	1.4
9	Unknown	130	0.9
	Missing	2	0%

HIST8522 - F130 Breast Histology 8522 Subclass

Col 18

Subclassification for Breast Histology 8522.

Usage Notes:

Not collected on early versions of F130.

Value	Description	N	%
0	Not Applicable	8,050	56.4
1	Ductal in situ plus lobular in situ	139	1
2	Ductal invasive plus lobular in situ	337	2.4
3	Ductal invasive plus lobular invasive	715	5
4	Lobular invasive plus ductal in situ	207	1.5
5	Invasive cancer, ductal and lobular nos	327	2.3
	Missing	4,492	31.5%

ERASSAY - F130 Estrogen receptor assay

Col 19

Value	Description	N	%
1	Positive	10,631	74.5
2	Negative	1,841	12.9
3	Borderline	15	0.1
8	Ordered/Results not available	179	1.3
9	Unknown/Not done	1,597	11.2
	Missing	4	0%

ERDY - F130 Days to Estrogen Assay

Col 20

N	Missing	Min	Max	Mean	StdDev
12,499	1,768	1	10,543	3,977.497	2,539.52

ERTYPE - F130 Type of Estrogen Assay

Col 21

Value	Description	N	%
1	fmol/mg protein	121	0.8
2	ICC/IHC	11,278	79
8	Other	143	1
9	Unknown	952	6.7
	Missing	1,773	12.4%

PRASSAY - Progesterone receptor assay

Col 22

Value	Description	N	%
1	Positive	8,897	62.4
2	Negative	3,310	23.2
3	Borderline	53	0.4
8	Ordered/Results not available	187	1.3
9	Unknown/Not done	1,815	12.7
	Missing	5	0%

PRDY - F130 Days to Progesterone receptor assay

Col 23

N	Missing	Min	Max	Mean	StdDev
12,277	1,990	1	10,543	3,972.331	2,533.428

PRTYPE - F130 Type of Progesterone receptor assay

Col 24

Value	Description	N	%
1	fmol/mg protein	119	0.8
2	ICC/IHC	11,099	77.8
8	Other	141	1
9	Unknown	914	6.4
	Missing	1,994	14%

HER2NEU - F130 Her 2/Neu

Col 25

Usage Notes:

Not collected on early versions of F130.

Value	Description	N	%
1	Positive	1,284	9
2	Negative	8,108	56.8
3	Borderline	101	0.7
8	Ordered/Results not available	116	0.8
9	Unknown/Not done	2,499	17.5
	Missing	2,159	15.1%

HER2NEUDY - F130 Days to HER 2/NEU

Col 26

Usage Notes:

Not collected on early versions of F130.

N	Missing	Min	Max	Mean	StdDev
9,532	4,735	7	10,543	4,355.71	2,432.418

AGEDX - Age at diagnosis

Col 27

N	Missing	Min	Max	Mean	StdDev
14,267	0	50	103	72.806	8.306